IL102390A - Tumour antigen specific monoclonal antibody its use and cell line producing the antibody and pharmaceutical compositions containing said antibody - Google Patents

Tumour antigen specific monoclonal antibody its use and cell line producing the antibody and pharmaceutical compositions containing said antibody

Info

Publication number
IL102390A
IL102390A IL10239092A IL10239092A IL102390A IL 102390 A IL102390 A IL 102390A IL 10239092 A IL10239092 A IL 10239092A IL 10239092 A IL10239092 A IL 10239092A IL 102390 A IL102390 A IL 102390A
Authority
IL
Israel
Prior art keywords
antibody
monoclonal antibody
cell line
antigen
cells
Prior art date
Application number
IL10239092A
Other languages
English (en)
Other versions
IL102390A0 (en
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Publication of IL102390A0 publication Critical patent/IL102390A0/xx
Publication of IL102390A publication Critical patent/IL102390A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1063—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from stomach or intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1057—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from liver or pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Optics & Photonics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL10239092A 1991-07-03 1992-07-02 Tumour antigen specific monoclonal antibody its use and cell line producing the antibody and pharmaceutical compositions containing said antibody IL102390A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9102074A SE9102074D0 (sv) 1991-07-03 1991-07-03 Tomour antigen specific antibody

Publications (2)

Publication Number Publication Date
IL102390A0 IL102390A0 (en) 1993-01-14
IL102390A true IL102390A (en) 1996-01-19

Family

ID=20383243

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10239092A IL102390A (en) 1991-07-03 1992-07-02 Tumour antigen specific monoclonal antibody its use and cell line producing the antibody and pharmaceutical compositions containing said antibody

Country Status (19)

Country Link
US (1) US5552293A (da)
EP (1) EP0521842B1 (da)
JP (1) JP3194020B2 (da)
KR (1) KR100246681B1 (da)
AT (1) ATE171193T1 (da)
AU (2) AU2292092A (da)
CA (1) CA2073124C (da)
DE (1) DE69226990T2 (da)
DK (1) DK0521842T3 (da)
EE (1) EE03031B1 (da)
ES (1) ES2124250T3 (da)
FI (1) FI109207B (da)
HU (2) HU218084B (da)
IE (1) IE80841B1 (da)
IL (1) IL102390A (da)
NO (1) NO315472B1 (da)
NZ (1) NZ243435A (da)
SE (1) SE9102074D0 (da)
WO (2) WO1993001302A1 (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9402430L (sv) 1994-07-11 1996-01-12 Pharmacia Ab Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten
SE9601245D0 (sv) 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
TW517061B (en) 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
BRPI9809391B8 (pt) * 1997-04-14 2021-05-25 Amgen Res Munich Gmbh processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
JP2004537976A (ja) 2001-03-15 2004-12-24 インターナショナル バイオイムン システムズ，インコーポレーテッド 膵癌のモノクローナル抗体治療
DE10116552A1 (de) * 2001-04-03 2002-10-10 Abc Armbruster Biochemicals Verfahren zur Bestimmung der wirksamen Parathormon-Aktivität in einer Probe
JP2005532395A (ja) * 2002-07-02 2005-10-27 スミスクライン・ビーチャム・コーポレイション 新規な安定処方
US7390898B2 (en) 2002-08-02 2008-06-24 Immunogen Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
MXPA05011811A (es) 2003-05-20 2006-02-17 Immunogen Inc Agentes citotoxicos mejorados que comprenden nuevos maitansinoides.
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
ES2503719T3 (es) 2005-02-11 2014-10-07 Immunogen, Inc. Procedimiento para preparar conjugados de anticuerpos y de maitansinoides
AU2012241141B2 (en) * 2005-08-11 2015-08-20 Arpi Matossian-Rogers TCR-V-beta related peptides for treatment and diagnosis of autoimmune disease
KR101527334B1 (ko) * 2005-08-11 2015-06-09 알피 마토씨안-로저스 자가면역 질병의 치료 및 진단용 ｔｃｒ-ｖ-베타 관련 펩티드
CA3000520C (en) 2005-08-24 2023-04-04 Immunogen, Inc. Process for preparing antibody maytansinoid conjugates
MX2011001445A (es) 2008-08-05 2011-04-05 Toray Industries Metodo para detectar cancer.
SG10201810743WA (en) 2009-06-03 2018-12-28 Immunogen Inc Conjugation methods
ME03353B (me) 2011-03-29 2019-10-20 Immunogen Inc Priprema konjugata antitela i majtanzinoida jednostepenim postupkom
MY171008A (en) 2011-03-29 2019-09-23 Immunogen Inc Preparation of maytansinoid antibody conjugates by a one-step process
RU2661083C2 (ru) 2012-10-04 2018-07-11 Иммуноджен, Инк. Использование пвдф-мембраны для очистки конъюгатов клеточно-связывающий агент - цитотоксический агент
WO2015076425A1 (ja) * 2013-11-25 2015-05-28 リンク・ジェノミクス株式会社 新規モノクローナル抗体
US10413615B2 (en) 2014-11-19 2019-09-17 Immunogen, Inc. Process for preparing cell-binding agent-cytotoxic agent conjugates
KR20250071286A (ko) 2016-01-10 2025-05-21 네오티엑스 테라퓨틱스 엘티디. 면역강화제에 의해 증진되는 초항원 매개된 암 면역요법
TW201731532A (zh) 2016-02-05 2017-09-16 伊繆諾金公司 用於製備細胞結合劑-細胞毒性劑結合物之有效方法
CN107167590B (zh) * 2017-04-14 2019-03-08 江苏福隆生物技术有限公司 糖类抗原242的板式化学发光法检测试剂盒及制备方法
US20200256880A1 (en) * 2017-08-16 2020-08-13 The Broad Institute, Inc. Neuronal Assay Method Involving Calcineurin
CA3139899A1 (en) 2019-05-15 2020-11-19 Neotx Therapeutics Ltd. Cancer treatment
CN115484978A (zh) 2020-03-05 2022-12-16 尼奥克斯医疗有限公司 使用免疫细胞治疗癌症的方法和组合物
EP4732850A1 (en) 2024-10-25 2026-04-29 Antelope Therapeutics SAS Antibody-drug conjugates and their uses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4752569A (en) * 1984-06-21 1988-06-21 The Regents Of The University Of California Sialylated Lewisx epitope, antibodies and diagnosis
US4904596A (en) * 1985-08-07 1990-02-27 Fred Hutchinson Cancer Research Center Hybridoma antibody (FH6) defining a human cancer-associated difucoganglioside
SE8902043L (sv) * 1988-11-10 1990-05-11 Pharmacia Ab Foerfarande foer karakterisering av makromolekyler
AU657483B2 (en) * 1990-07-20 1995-03-16 Pharmacia Ab Heterobifunctional reagents and conjugates with oxaalkylene units for amphiphilic bridge structures
DE69122777T2 (de) * 1990-07-20 1997-04-10 Pharmacia & Upjohn Ab, Stockholm Zielgerichtete spezifische antikörper-superantigen konjugate und ihre präparation

Also Published As

Publication number Publication date
CA2073124C (en) 2007-06-19
FI109207B (fi) 2002-06-14
IL102390A0 (en) 1993-01-14
JPH05276987A (ja) 1993-10-26
IE922188A1 (en) 1993-01-13
NZ243435A (en) 1994-10-26
HU211512A9 (en) 1995-11-28
AU1942592A (en) 1993-01-07
JP3194020B2 (ja) 2001-07-30
KR100246681B1 (ko) 2000-04-01
WO1993001302A1 (en) 1993-01-21
WO1993001303A1 (en) 1993-01-21
EP0521842A3 (da) 1994-01-26
DE69226990T2 (de) 1999-03-25
IE80841B1 (en) 1999-03-24
FI935970A0 (fi) 1993-12-31
NO934777D0 (no) 1993-12-22
AU658198B2 (en) 1995-04-06
CA2073124A1 (en) 1993-01-04
EP0521842B1 (en) 1998-09-16
DE69226990D1 (de) 1998-10-22
EE03031B1 (et) 1997-08-15
HUT71193A (en) 1995-11-28
EP0521842A2 (en) 1993-01-07
SE9102074D0 (sv) 1991-07-03
HU9400011D0 (en) 1994-05-30
AU2292092A (en) 1993-02-11
US5552293A (en) 1996-09-03
ES2124250T3 (es) 1999-02-01
DK0521842T3 (da) 1999-06-14
FI935970L (fi) 1993-12-31
HU218084B (hu) 2000-05-28
NO315472B1 (no) 2003-09-08
ATE171193T1 (de) 1998-10-15
NO934777L (no) 1994-02-11

Similar Documents

Publication Publication Date Title
US5552293A (en) Tumor antigen specific antibody
CN113544156B (zh) 抗Claudin18.2抗体及其应用
JP4124486B2 (ja) ガン細胞を特異的に検出する抗原結合フラグメント、このフラグメントをコードするヌクレオチド、ならびにガンの予防および検出のためのその使用
JP3492373B2 (ja) モノクローナル抗体
RU2266298C2 (ru) Антитела к антигену эпителиальных опухолей желудочно-кишечного тракта человека, родственному альфа 6 бета 4 интегрину
JP2000511421A5 (da)
US11608384B2 (en) Humanized anti-TPBG antibody, preparation method therefor, conjugate thereof, and applications
AU2017358360B2 (en) Antibody binding to carbonic anhydrase and use thereof
CN113906053B (zh) 抗cea抗体及其应用
EP3619237B1 (en) Antibodies against carcinoembryonic antigen for cancer therapy and diagnosis
CA3062233C (en) Antibodies against carcinoembryonic antigen for cancer therapy and diagnosis
CA2255540C (en) Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
AU7243200A (en) Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers

Legal Events

Date Code Title Description
FF Patent granted
HC Change of name of proprietor(s)
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees